valeant pharmaceuticals
'Pharma Bro' Martin Shkreli gives SBF tips for potential prison stint
Ex-con “Pharma Bro” Martin Shkreli offered some jailhouse wisdom to alleged crypto conman Sam Bankman-Fried if he ends up going to prison: Shave your head and brush up on rap...
Judge seems OK with Ackman's $290M Allergan settlement
Bill Ackman and Valeant Pharmaceuticals can breathe a sigh of relief — for now. A federal judge in California indicated Tuesday that he would grant preliminary approval to a $290...
Ackman looks to persuade judge $290M Allergan settlement is fair
Bill Ackman is going to try and hold onto a little cash on Tuesday. Lawyers for the embattled hedgie will appear before a federal judge in Los Angeles in an...
Ackman's Pershing Square fund to slash management fee
Hedgie Bill Ackman on Wednesday ripped a page from a discount retailer’s playbook — he put his product on sale. Ackman’s Pershing Square fund — after posting losses in each...
Judge has questions for Ackman about proposed settlement
Just when he thought he was out, hedgie Bill Ackman is being pulled back into his disastrous Valeant Pharmaceuticals relationship by a California judge. The judge on Tuesday said that...
Ackman pays $194M to settle suit with 'absolutely no merit'
Bill Ackman said he’s shelling out $194 million to settle a three-year-old lawsuit — even as he insisted the case against him has “absolutely no merit.” The billionaire investor revealed...
John Paulson joins Valeant's board despite heavy losses
Billionaire John Paulson is doubling down on Valeant Pharmaceuticals. The hedge-fund tycoon said Monday he is joining the board of the scandal-ridden pharma giant — despite the fact that he’s...
Ackman: 2-and-20 doesn't work anymore for hedge funds
After two years of double-digit losses, Bill Ackman is hoping for a comeback. “I got something to prove,” Ackman, the billionaire behind hedge fund Pershing Square, said at an afternoon...
Bill Ackman loves his new stock pick, but won't say what it is
Bill Ackman is talking up his favorite investment, big-time — except for the fact that he won’t tell anybody what it is. The hedge-fund billionaire has spent the past several...
Scandal-ridden pharma giant wants to change its name
Valeant Pharmaceuticals is considering (yet another) makeover. Having weathered continued accusations of financial malfeasance for the past two years, the scandal-plagued pharma giant has changed its C-suite and made a...
Dealing with online brokerage firms can be an ordeal
Dear John, Several weeks ago I wrote to you regarding a most unpleasant and I believe dishonest experience with [online brokerage] TD Ameritrade. I have been investing with this company...
'I profoundly apologize': Ackman regrets costly Valeant failure
Bill Ackman has finally apologized for his disastrous investment in Valeant Pharmaceuticals. “While I and the rest of the Pershing Square team have suffered significant losses from this failed investment...
Bill Ackman can't escape Valeant lawsuit
Bill Ackman may have sold his stake in Valeant Pharmaceuticals but he can’t kick the habit as lawsuits continue. On Wednesday, California US District Judge David Carter permitted Allergan shareholders...
Ackman dumps Valeant stake hours after being squeezed on Herbalife
Bill Ackman screamed “uncle” on one of his worst bets ever — while getting squeezed by Carl Icahn on his second-worst bet. The New York tycoon behind Pershing Square Capital...
Pharma giants' stock prices hit by another Trump tweet
Donald Trump has pharma giants and their big-name investors reaching for aspirin again. Shares of major drug companies tumbled Tuesday after the President tweeted: “I am working on a new...
Pharma giant Valeant looking more desperate than ever
Valeant can’t seem to catch a break. Shares of the scandal-plagued pharmaceutical giant got hammered Monday after the company announced that it’s looking to push back the due date of...
Valeant shares tank despite better-than-expected 4Q results
Investors weren’t buying Valeant boss Joseph Papa’s promises of a “new Valeant” Tuesday morning. Despite beating analyst estimates, shares of the beleaguered pharmaceutical giant fell as much 10 percent after...
Pershing Square and Valeant agree to split legal costs
Bill Ackman’s Pershing Square and Valeant Pharmaceuticals have reached an agreement to evenly split legal costs in their nearly two-year long battle against Allergan shareholders. In June 2015, Allergan shareholders...
Valeant stock surges following $1.3B L'Oreal deal
Valeant’s badly blemished stock is getting a makeover. Shares of the scandal-plagued pharma giant surged as much as 14 percent, to $17.53 a share, in early Tuesday trades after it...
Valeant Pharmaceuticals hits 52-week low amid Ackman sell-off
That thud coming from Wall Street on Thursday was the sound of Valeant Pharmaceuticals’ shares slamming against a 52-week low. The Canadian drugmaker’s week from hell continued with a wallop...